Lean MASLD represents a distinct phenotype with milder histologic disease but similar clinical outcomes compared with overweight/obese MASLD, and the FIB-4 demonstrated lower accuracy for predicting advanced fibrosis in lean vs overweight/obese MASLD.
L. de Avila, K. Al-Naamani, M. Papatheodoridi et al.· Journal of the American Medi...· 1 citation
BACKGROUND AND AIMS
The evolution of non-invasive tests of liver fibrosis during follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remains difficult to interpret in clinical practice. We aimed to translate the dynamics of non-invasive tests into a personalized prediction of liv...
C. Moreau, M. Roux, J. Riou et al.· Clinical Gastroenterology an...· 0 citations
Summary Background The cardiovascular-kidney-liver-metabolic (CKLM) framework represents the multi-organ interplay of systemic metabolic disorders that drive the global burden of cardiovascular diseases (CVD). Methods This study is a descriptive epidemiological analysis of the Global Burden of Disease Study 2023 that e...
J. Jayabaskaran, Haryo Raden Himan, S. Nagarajan et al.· EClinicalMedicine· 0 citations
Individuals with MASLD who experience a CVD event have a higher subsequent risk of long-term LREs, and the value of targeted liver monitoring for high-risk individuals after CVD and integrated heart-liver co-management is underscored.
Li-You Lian, Qin-Fen Chen, Tianyi Xia et al.· Metabolism: Clinical and Exp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
